Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
| Treament | Trials | |||||
|---|---|---|---|---|---|---|
| Demonstrated or suggested benefit | Inconclusive results | Uncertain results | Safety results | |||
| ivermectin | none | inconclusive results for: Emergency room visit or hospitalization; deaths; hospitalization or death; clinical deterioration; clinical improvement; clinical improvement (21-day); clinical improvement (28-day); clinical improvement (time to event analysis only); hospitalization; mechanical ventilation; Recovery (time to event analysis only); viral clearance ; viral clearance by day 14; viral clearance by day 7; serious adverse events; adverse events | - | - | ||
| chloroquine and derivatives | none | inconclusive results for: deaths; clinical deterioration; clinical improvement; clinical improvement (14-day); hospitalization; mechanical ventilation; viral clearance ; viral clearance by day 14; viral clearance by day 7; ICU admission; adverse events | - | - | ||
| azithromycin | none | inconclusive results for: deaths; hospitalization or death; A EFFACER PCR-negative (end of follow-up); clinical improvement; clinical improvement (14-day); clinical improvement (time to event analysis only); hospitalization; mechanical ventilation; ICU admission | suggested 715.0-fold increase in viral clearance but the degree if certainty is unassessable | - | ||
| fluvoxamine | inconclusive results for: Emergency room visit or hospitalization; death D28; deaths; deaths (time to event analysis only); hospitalization or death; hospitalization; viral clearance ; viral clearance by day 7; recovery; AE leading to drug discontinuation; serious adverse events; adverse events | - | ||||
| hydroxychloroquine plus macrolides | none | inconclusive results for: deaths; clinical improvement; hospitalization; viral clearance ; viral clearance by day 14; viral clearance by day 7 | - | - | ||
| molnupiravir | inconclusive results for: AE leading to drug discontinuation; serious adverse events; adverse events | demonstrated 52 % decrease in hospitalization or death but the degree if certainty is unassessable suggested 51 % decrease in hospitalization but the degree if certainty is unassessable suggested 14.5-fold increase in viral clearance but the degree if certainty is unassessable suggested 14.5-fold increase in viral clearance by day 7 but the degree if certainty is unassessable | - | |||
| lopinavir/ritonavir | none | inconclusive results for: deaths; hospitalization; viral clearance ; viral clearance by day 14 | - | - | ||
| nirmatrelvir / ritonavir (Paxlovid) | none | inconclusive results for: related AE (TRAE); related SAE (TRSAE) | suggested 96 % decrease in death D28 but the degree if certainty is unassessable suggested 96 % decrease in deaths but the degree if certainty is unassessable demonstrated 88 % decrease in hospitalization or death but the degree if certainty is unassessable | - | ||
| nitazoxanide | none | - | - | - | ||
| remdesivir | none | inconclusive results for: death D28; deaths; AE leading to drug discontinuation; adverse events | demonstrated 87 % decrease in hospitalization or death but the degree if certainty is unassessable suggested 72 % decrease in hospitalization but the degree if certainty is unassessable suggested 75 % decrease in serious adverse events but the degree if certainty is unassessable | - | ||
| sofosbuvir and daclatasvir | none | inconclusive results for: hospitalization | - | - | ||
| zinc | none | - | - | - | ||
| Amantadine | 0 | - | - | - | - | |
| ASC09/ritonavir | 0 | - | - | - | - | |
| azvudine | 0 | - | - | - | - | |
| baloxavir marboxil | 0 | - | - | - | - | |
| bromhexine | 0 | - | - | - | - | |
| carrimycin | 0 | - | - | - | - | |
| danoprevir / ritonavir | 0 | - | - | - | - | |
| darunavir cobicistat | 0 | - | - | - | - | |
| doxycycline | 0 | - | - | - | - | |
| Emtricitabine/tenofovir plus colchicine plus rosuvastatin | 0 | - | - | - | - | |
| Ensitrelvir (XOCOVA) | 0 | - | - | - | - | |
| favipiravir | 0 | - | - | - | - | |
| favipiravir plus interferon | 0 | - | - | - | - | |
| Interferon plus lopinavir/ritonavir | 0 | - | - | - | - | |
| leronlimab | 0 | - | - | - | - | |
| lopinavir / ritonavir plus ribavirin | 0 | - | - | - | - | |
| lopinavir/ritonavir plus chloroquine | 0 | - | - | - | - | |
| Lopinavir/ritonavir plus hydroxychloroquine | 0 | - | - | - | - | |
| lopinavir/ritonavir plus interferon ß-1a | 0 | - | - | - | - | |
| lopinavir/ritonavir, ribavirin and interferon beta-1b | 0 | - | - | - | - | |
| niclosamide | 0 | - | - | - | - | |
| opaganib | 0 | - | - | - | - | |
| oseltamivir | 0 | - | - | - | - | |
| oseltamivir plus chloroquin | 0 | - | - | - | - | |
| ribavirin | 0 | - | - | - | - | |
| ritonavir | 0 | - | - | - | - | |
| sofosbuvir | 0 | - | - | - | - | |
| sofosbuvir and ledipasvir | 0 | - | - | - | - | |
| tenofovir/emtricitabine | 0 | - | - | - | - | |
| tenofovir/emtricitabine plus hydroxychloroquine | 0 | - | - | - | - | |
| tranexamic acid | 0 | - | - | - | - | |
| tranilast | 0 | - | - | - | - | |
| triazavirin | 0 | - | - | - | - | |
| umifenovir (arbidol) | 0 | - | - | - | - | |
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
